Depression represents a global mental health concern, and disproportionally affects women
as they are twice more likely to be diagnosed than men. In this review, we provide a …

Major depressive disorder (MDD) is a debilitating illness characterized by neuroanatomical
and functional alterations in limbic structures, notably the prefrontal cortex (PFC), that can be …

Background Post-partum depression is associated with substantial morbidity, and improved
pharmacological treatment options are urgently needed. We assessed brexanolone …

Importance Postpartum depression (PPD) is one of the most common medical complications
during and after pregnancy, negatively affecting both mother and child. Objective To …

Pregnancy is a complex and vulnerable period that presents a number of challenges to
women, including the development of postpartum psychiatric disorders (PPDs). These …

Background Post-partum depression is a serious mood disorder in women that might be
triggered by peripartum fluctuations in reproductive hormones. This phase 2 study …

Major depressive disorder is a common psychiatric disorder associated with marked
suffering, morbidity, mortality, and cost. The World Health Organization projects that by 2030 …

Objective: Postpartum depression (PPD) is a common perinatal complication with adverse
maternal and infant outcomes. This study investigated the efficacy and safety of zuranolone …

Therapeutic medications for the treatment of depression have serious limitations, particularly
delayed onset and low rates of efficacy. However, the discovery that a single subanesthetic …

Background Brexanolone is currently the only treatment specifically approved for postpartum
depression (PPD) in the United States, based on the results from one Phase 2 and two …